Turn Therapeutics, Inc. (TTRX)
12.00
+0.61
(+5.36%)
USD |
NASDAQ |
Oct 09, 16:00
11.95
-0.05
(-0.42%)
After-Hours: 20:00
Turn Therapeutics Enterprise Value : 353.29M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 353.29M |
| October 08, 2026 | 335.12M |
| October 07, 2026 | 356.27M |
| October 06, 2026 | 342.56M |
| October 05, 2026 | 364.01M |
| October 02, 2026 | 392.91M |
| October 01, 2026 | 392.31M |
| September 30, 2026 | 424.48M |
| September 29, 2026 | 395.29M |
| September 28, 2026 | 384.27M |
| September 25, 2026 | 367.88M |
| September 24, 2026 | 390.82M |
| September 23, 2026 | 398.27M |
| September 22, 2026 | 451.29M |
| September 21, 2026 | 452.78M |
| September 18, 2026 | 440.87M |
| September 17, 2026 | 407.50M |
| September 16, 2026 | 404.52M |
| September 15, 2026 | 396.78M |
| September 14, 2026 | 396.48M |
| September 11, 2026 | 373.84M |
| September 10, 2026 | 394.40M |
| September 09, 2026 | 405.42M |
| September 08, 2026 | 372.95M |
| September 04, 2026 | 287.75M |
| Date | Value |
|---|---|
| September 03, 2026 | 295.80M |
| September 02, 2026 | 283.88M |
| September 01, 2026 | 288.35M |
| August 31, 2026 | 281.80M |
| August 28, 2026 | 288.95M |
| August 27, 2026 | 296.99M |
| August 26, 2026 | 282.69M |
| August 25, 2026 | 285.67M |
| August 24, 2026 | 284.18M |
| August 21, 2026 | 277.63M |
| August 20, 2026 | 280.01M |
| August 19, 2026 | 288.35M |
| August 18, 2026 | 293.41M |
| August 17, 2026 | 291.03M |
| August 14, 2026 | 280.90M |
| August 13, 2026 | 289.54M |
| August 12, 2026 | 309.80M |
| August 11, 2026 | 300.27M |
| August 10, 2026 | 281.80M |
| August 07, 2026 | 305.93M |
| August 06, 2026 | 282.10M |
| August 05, 2026 | 276.73M |
| August 04, 2026 | 279.41M |
| August 03, 2026 | 259.16M |
| July 31, 2026 | 244.86M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.932B |
| Corcept Therapeutics, Inc. | 12.78B |
| Veru, Inc. | 18.84M |
| Johnson & Johnson | 657.89B |
| Eli Lilly & Co. | 1.156T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.850M |
| Total Expenses (Quarterly) | 5.850M |
| EPS Diluted (Quarterly) | -0.1964 |
| Earnings Yield | -2.40% |
| Normalized Earnings Yield | -2.468 |